Effects of tigecycline and vancomycin administration on established Clostridium difficile infection

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 3, 2015, Pages 1596-1604

  Theriot, Casey M ^a   Schumacher, Cassie A ^a,b   Bassis, Christine M ^a   Seekatz, Anna M ^a   Young, Vincent B ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Swift Bioscience   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOPERAZONE; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; MINOCYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM DETECTION; C57BL 6 MOUSE; CECUM; CLOSTRIDIUM DIFFICILE INFECTION; COLON; CONTROLLED STUDY; DRUG CYTOTOXICITY; FECES; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; SPOROGENESIS; TREATMENT OUTCOME; VERO CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; CECUM; CLOSTRIDIUM DIFFICILE; COLON; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; FEMALE; MALE; MICE; MICE, INBRED C57BL; MINOCYCLINE; VANCOMYCIN;

EID: 84923240963     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04296-14     Document Type: Article

References (32)

1. Hall JC, O'Toole E. 1935. Intestinal flora in new-born infants with a description of anewpathogenic anaerobe, Bacillus difficilis. Am J Dis Child 49:390-402. http://dx.doi.org/10.1001/archpedi.1935.01970020105010.
2. McCollum DL, Rodriguez JM. 2012. Detection, treatment, and prevention of Clostridium difficile infection. Clin Gastroenterol Hepatol 10:581-592. http://dx.doi.org/10.1016/j.cgh.2012.03.008.
3. Stanley JD, Bartlett JG, Dart BW, IV, Ashcraft JH. 2013. Clostridium difficile infection. Curr Probl Surg 50:302-337. http://dx.doi.org/10.1067/j.cpsurg.2013.02.004.
4. Bartlett JG. 1984. Antibiotic-associated colitis. Dis Mon 30:1-54. http://dx.doi.org/10.1016/0011-5029(84)90009-9.
5. Dubberke ER, Wertheimer AI. 2009. Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol 30:57-66. http://dx.doi.org/10.1086/592981.
6. Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW. 2010. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 74:309-318. http://dx.doi.org/10.1016/j.jhin.2009.10.016.
7. Dubberke ER, Olsen MA. 2012. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 55(Suppl 2):S88-S92. http://dx.doi.org/10.1093/cid/cis335.
8. U.S. FDA. 2011. FDA approves treatment for Clostridium difficile infection. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm257024.htm.
9. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31:431-455. http://dx.doi.org/10.1086/651706.
10. Reynolds PE. 1989. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 8:943-950. http://dx.doi.org/10.1007/BF01967563.
11. Kasbekar N. 2006. Tigecycline: a new glycylcycline antimicrobial agent. Am J Health System Pharm 63:1235-1243. http://dx.doi.org/10.2146/ajhp050487.
12. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. 2007. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 51:2716-2719. http://dx.doi.org/10.1128/AAC.01623-06.
13. Herpers BL, Vlaminckx B, Burkhardt O, Blom H, Biemond-Moeniralam HS, Hornef M, Welte T, Kuijper EJ. 2009. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 48:1732-1735. http://dx.doi.org/10.1086/599224.
14. Lu C-L, Liu C-Y, Liao C-H, Huang Y-T, Wang H-P, Hsueh P-R. 2010. Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole. Int J Antimicrob Agents 35:311-312. http://dx.doi.org/10.1016/j.ijantimicag.2009.11.008.
15. Hawser SP. 2010. Activity of tigecycline against recent European clinical isolates of Clostridium difficile. Int J Antimicrob Agents 35:97-98. http://dx.doi.org/10.1016/j.ijantimicag.2009.09.009.
16. Kopterides P, Papageorgiou C, Antoniadou A, Papadomichelakis E, Tsangaris I, Dimopoulou I, Armaganidis A. 2010. Failure of tigecycline to treat severe Clostridium difficile infection. Anaesthesia Intens Care 38:755.
17. Thomas A, Khan F, Uddin N, Wallace MR. 2014. Tigecycline for severe Clostridium difficile infection. Int J Infect Dis 26:171-172. http://dx.doi.org/10.1016/j.ijid.2014.04.025.
18. Jump RLP, Li Y, Pultz MJ, Kypriotakis G, Donskey CJ. 2011. Tigecycline exhibits inhibitory activity against Clostridiumdifficile in the colon of mice and does not promote growth or toxin production. Antimicrob Agents Chemother 55:546-549. http://dx.doi.org/10.1128/AAC.00839-10.
19. Theriot CM, Koumpouras CC, Carlson PE, Bergin II, Aronoff DM, Young VB. 2011. Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains. Gut Microbes 2:326-334. http://dx.doi.org/10.4161/gmic.19142.
20. Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB. 2011. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile infection. Gut Microbes 2:145-158. http://dx.doi.org/10.4161/gmic.2.3.16333.
21. Perez J, Springthorpe VS, Sattar SA. 2011. Clospore: a liquid medium for producing high titers of semi-purified spores of Clostridium difficile. J AOAC Int 94:618-626.
22. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. 2008. A mouse model of Clostridium difficile-associated disease. Gastroenterology 135:1984-1992. http://dx.doi.org/10.1053/j.gastro.2008.09.002.
23. Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, Raisen C, Goulding D, Rad R, Schreiber F, Brandt C, Deakin LJ, Pickard DJ, Duncan SH, Flint HJ, Clark TG, Parkhill J, Dougan G. 2012. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 8:e1002995. http://dx.doi.org/10.1371/journal.ppat.1002995.
24. Holland T. 2001. A survey of discriminant methods used in toxicological histopathology. Toxicol Pathol 29:269-273. http://dx.doi.org/10.1080/019262301317052567.
25. Holland T. 2005. The comparative power of the discriminant methods used in toxicological pathology. Toxicol Pathol 33:490-494. http://dx.doi.org/10.1080/01926230590965382.
26. Bassis CM, Theriot CM, Young VB. 2014. Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection. Antimicrob Agents Chemother 58:2767-2774. http://dx.doi.org/10.1128/AAC.02262-13.
27. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, Lesniewski RA, Oakley BB, Parks DH, Robinson CJ, Sahl JW, Stres B, Thallinger GG, Van Horn DJ, Weber CF. 2009. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 75:7537-7541. http://dx.doi.org/10.1128/AEM.01541-09.
28. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glockner FO. 2013. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res 41: D590-D596. http://dx.doi.org/10.1093/nar/gks1219.
29. Wang Q, Garrity GM, Tiedje JM, Cole JR. 2007. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 73:5261-5267. http://dx.doi.org/10.1128/AEM.00062-07.
30. Aldape MJ, Heeney DD, Bryant AE, Stevens DL. 2015. Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile. J Antimicrob Chemother 70:153-159. http://dx.doi.org/10.1093/jac/dku325.
31. Garneau JR, Valiquette L, Fortier LC. 2014. Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. BMC Infect Dis 14:29. http://dx.doi.org/10.1186/1471-2334-14-29.
32. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, Young VB. 2008. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 197:435-438. http://dx.doi.org/10.1086/525047.